风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

磷酸二酯酶4的新型抑制剂Brilacidin治疗自身免疫和炎症疾病的潜力

2018-10-14 MedSci MedSci原创

Brilacidin磷酸二酯酶4炎症
关注

Innovation生物制药公司近日提供了磷酸二酯酶4（PDE4）的新型抑制剂Brilacidin的最新信息。磷酸二酯酶4（PDE4）被认为是炎症治疗的新机制。

Innovation生物制药公司近日提供了磷酸二酯酶4（PDE4）的新型抑制剂Brilacidin的最新信息。磷酸二酯酶4（PDE4）被认为是炎症治疗的新机制。PDE4抑制剂，例如apremilast和crisaborole已陆续用于治疗各种自身免疫和炎性疾病。目前正在研究PDE4抑制剂治疗炎性肠病（IBD）的可能性。

由于介导多种免疫调节功能，防御素在皮肤和粘膜表面以及中性粒细胞中广泛表达，产生的小型抗微生物肽在介导人类健康和疾病中起关键作用。Brilacidin的设计以防御素为模型，已被证明是免疫反应的有效调节剂。它能够抑制各种促炎介质（例如，TNF-α，IL-1β，IL-8，IL-6，MMP-9，MCP-1）。Brilacidin作用机制的一个潜在核心就是抑制磷酸二酯酶4（PDE4）以及磷酸二酯酶3（PDE3）的能力以调节环磷酸腺苷（cAMP）途径，这是一种既定的治疗靶点。

更详细地，临床前研究已经证明Brilacidin以剂量依赖性方式在体外抑制PDE4B2和PDE3A。在基于细胞的测定中，表明Brilacidin具有良好的细胞膜通透性。


原始出处：

http://www.firstwordpharma.com/node/1597080#axzz5Trc0A3L7

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-08-29 xlxchina

    #CID#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-01-17 仁心济世

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-03-20 zhouqu_8

    #acid#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-01-03 经常头晕

    #炎症疾病#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2019-09-19 医者仁心

    #磷酸二酯酶4#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1991602, encodeId=4b1419916021c, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Aug 29 13:52:00 CST 2019, time=2019-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851812, encodeId=1564185181223, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Jan 17 20:52:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911438, encodeId=ff3a191143844, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Mar 20 13:52:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070770, encodeId=b1a920e077053, content=<a href='/topic/show?id=83c06e051bf' target=_blank style='color:#2F92EE;'>#炎症疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67051, encryptionId=83c06e051bf, topicName=炎症疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu Jan 03 02:52:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045451, encodeId=c6a2204545180, content=<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73849, encryptionId=0092e38496e, topicName=磷酸二酯酶4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Sep 19 18:52:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349307, encodeId=35f734930e3d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49fd2461250, createdName=1241a1f8m26暂无昵称, createdTime=Sun Oct 14 18:14:30 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 1241a1f8m26暂无昵称

    好

    0